Neuroblastoma
MONDO:0005072Neuroblastoma (NB) is the most common solid, extracranial childhood tumor. It is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system.
Also known as: neural Crest tumor, malignant, neuroblastoma, neuroblastoma (Schwannian Stroma-poor), neuroblastoma, malignant, NB
1623 clinical trials for this condition and its sub-types, 198 tagged with Neuroblastoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neuroblastoma
-
Cerebral neuroblastoma 4 trials
1 sub-type
-
Extracranial neuroblastoma 0 trials · 4 incl. sub-types
3 sub-types
- Olfactory neuroblastoma 4 trials Sub-types →
- Cervical neuroblastoma 0 trials
- Spinal cord neuroblastoma 0 trials
-
Differentiating neuroblastoma 0 trials
-
Dopaminergic neuroblastoma 0 trials
-
Mediastinum neuroblastoma 0 trials
1 sub-type
- Mediastinum ganglioneuroblastoma 0 trials
-
Retinal neuroblastoma 0 trials
-
Retroperitoneal neuroblastoma 0 trials
1 sub-type
- Adrenal gland neuroblastoma 0 trials Sub-types →
Most studied deeper sub-types
-
New combo therapy shows promise for kids with tough cancers
Disease control Stopped earlyThis study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…
Phase 1/2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody cocktail takes aim at tough childhood cancers
Disease control Stopped earlyThis early-phase trial tested two lab-made antibodies, magrolimab and dinutuximab, together in 12 children and young adults whose neuroblastoma or osteosarcoma had returned or stopped responding to treatment. The main goal was to find a safe dose and watch for side effects. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental cancer therapy targets tough tumors with radioactive precision
Disease control Stopped earlyThis early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …
Phase 1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tailored cancer cocktail tested for tough childhood tumor
Disease control Stopped earlyThis trial tested a personalized approach for children with relapsed or hard-to-treat neuroblastoma. Doctors used a tumor biopsy to find genetic changes and then assigned a combination of targeted drugs (ceritinib and ribociclib) to match those changes. The study was terminated e…
Phase 1 • Sponsor: Yael P Mosse • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer drug combo trial for kids halted early
Disease control Stopped earlyThis early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail shows promise for tough childhood cancers
Disease control Stopped earlyThis early-phase trial tested a combination of three drugs—ribociclib, topotecan, and temozolomide—in children with relapsed or refractory neuroblastoma and other solid tumors. The goal was to find a safe dose and see if the combination could shrink tumors. Only 12 children took …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New radioactive therapy targets tough childhood cancer
Disease control Stopped earlyThis study tested a radioactive drug called 67Cu-SARTATE in 21 children with high-risk neuroblastoma that had relapsed or not responded to treatment. The drug is designed to deliver radiation directly to tumor cells. The goal was to find the safest dose and see if it shrinks tumo…
Phase 1/2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:47 UTC
-
New hope for kids with tough neuroblastoma? trial tests stronger therapies
Disease control Stopped earlyThis phase 2 trial tested two stronger treatment plans for children with very high risk neuroblastoma whose cancer did not respond well to initial chemotherapy. The treatments combined radioactive therapy (mIBG), chemotherapy drugs (topotecan and thiotepa), and a stem cell transp…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 26, 2026 13:21 UTC